Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2038)	5/14/2003 6:29:07 PM
From: keokalani'nui	Respond to of 2243

Latest BVF 13F, 3/31/03, sorted ascending: Viropharma Inc. 45 Intrabiotics Pharmaceuticals 61 Aclara Biosciences, Inc. 74 Epimmune Inc. 86 Paradigm Genetics, Inc. 117 Amylin Pharmaceuticals 162 Cadus Pharmaceuticals 307 Genome Therapeutics Corp. 324 Protein Polymer Technologies 325 Icos Corp. 357 Immunogen Inc. 470 Zonagen Inc. 539 Seattle Genetics, Inc. 988 Titan Pharmaceuticals 1,165 QLT, Inc. 1,333 Texas Biotechnology Corp 1,751 Cortech, Inc. 1,990 Insmed Inc. 2,249 Autoimmune Inc. 2,524 Medarex Inc. 2,917 Pharmacyclics, Inc. 3,222 Biocryst Pharmaceuticals Inc. 3,360 Neurogen Corp. 4,521 Johnson & Johnson 5,845 Advanced Magnetics, Inc. 5,980 Arqule, Inc. 6,214 Curagen Corporation 6,399 Array BioPharma, Inc. 7,585 Applied Molecular Evolution 8,981 Atherogenics, Inc. 9,819 Corvas Int'l, Inc. 10,711 3-Dimensional Pharmaceutical 11,567 DOV Pharmaceutical, Inc. 12,542 Flamel Technologies, S.A. 12,981 OSI Pharmaceuticals 16,166 Repligen Corp. 17,812 Arena Pharmaceuticals, Inc. 50,392 Sorry, can't figure out how to square it up. ALso, the JnJ are puts.

To: Icebrg who wrote (2038)	5/19/2003 5:54:00 AM
From: Icebrg	Read Replies (1) \| Respond to of 2243

>>Spectrum Pharmaceuticals (SPPI)>> Raj continues to beef up his board. I hope it is positive that these apparently qualified people take up positions on the BoD. One thing is under all circumstances clear. They cannot be doing this for the pay. Erik Spectrum Pharmaceuticals Nominates Former Pfizer Senior Vice President to Board of Directors Monday May 19, 5:30 am ET Dr. Dilip Mehta Supervised Clinical Trials and New Drug Applications for Blockbuster Drugs Such as Zoloft and Viagra and is Currently an FDA Advisory Committee Member IRVINE, Calif., May 19 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI - News) announced that Dilip J. Mehta, M.D., Ph.D., has been nominated for election to the Company's Board of Directors. Dr. Mehta spent fifteen years at Pfizer Inc., most recently as Senior Vice President, U.S. Clinical Research. In this position, he was responsible for human clinical studies for Pfizer's drugs in the United States. Under his direction, the clinical research department had more than 25 drugs under active development with 1-2 major New Drug Applications (NDAs) filed each year. Among his many responsibilities, Dr. Mehta supervised submissions of NDAs for Cardura, Norvasc, Zoloft, Zithromax, Diflucan, Unasyn, Trovan, Viagra, Zeldox, and a number of other drugs/supplements. Many of these drugs have annual sales in excess of a billion dollars per year. Dr. Mehta also currently serves as a member of the Psychopharmacology Advisory Committee to the U.S. Food and Drug Administration. as well as Spectrum Pharmaceuticals Appoints Julius Vida, Ph.D. to Its Board of Directors Thursday May 15, 8:31 am ET IRVINE, Calif., May 15 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI - News) announced today that Julius A. Vida, Ph.D. has been appointed to fill a vacancy on the Company's board of directors. Dr. Vida will stand for re-election at the Company's shareholder meeting scheduled for June 20, 2003. Julius Vida, Ph.D. brings over 35 years of international pharmaceutical industry experience to Spectrum Pharmaceuticals. His responsibilities have included establishing international businesses in new pharmaceutical therapeutic areas, modernizing portfolios by licensing innovative products and developing contacts with private sector, academic and government agencies. During his career, Dr. Vida worked for Merck, Kendall Colgate and Bristol-Myers Squibb, and was a consultant to American Home Products and Pharmacia. During his 18 years at Bristol-Myers, he negotiated 25 major licensing agreements, including Taxol, Plavix, Avapro, Carboplatin, Cisplatin and Zerit, rising to the position of Vice President, Business Development, Licensing and Strategic Planning. Dr. Vida received his Ph.D. from the Carnegie Institute of Technology, did a Postdoctoral fellowship at Harvard University and received an MBA from Columbia University.